According to the last reported balance sheet, AbbVie had liabilities of US$41.9b due within 12 months, and liabilities of ...

New, more expensive migraine drugs are no more effective against the throbbing headaches than traditional painkillers, and ...

AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

The surge in global cancer cases is raising serious concerns among experts. A recent study published in Monday in Cancer, a ...

AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...

Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine (ELAHERE®) for the ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

The next frame shows the Ubrelvy logo in the backstage hallway along with a blue lit path. Frames six to seven then show Serena Williams walking down the blue lit path, no longer exhibiting migraine ...

The latest trading session saw AbbVie (ABBV) ending at $193.45, denoting a -1.16% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 0.03%. At the same time, the Dow ...

The stock's fall snapped a two-day winning streak.

With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the ...